Paper42017533
Reversible sorafenib-associated coagulopathy identified by viscoelastic testing in a dog with intranasal sarcoma.
Kim D and 4 others. J Vet Intern Med, 2026. Cited by 0 papers, by iCite.
Cite this record
ConductScience Library. Reversible sorafenib-associated coagulopathy identified by viscoelastic testing in a dog with intranasal sarcoma. Papers, record 42017533. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42017533
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Reversible sorafenib-associated coagulopathy identified by viscoelastic testing in a dog with intranasal sarcoma.
- PubMed
Topics11
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Dog Diseases | Major topic |
| Niacinamide | Major topic |
| Sarcoma | Major topic |
| Antineoplastic Agents | Major topic |
| Nose Neoplasms | Major topic |
| Phenylurea Compounds | Major topic |
| Blood Coagulation Disorders | Major topic |
| Animals | |
| Dogs | |
| Sorafenib | |
| Male |
Source PubMed
References15
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 18650514 | Sorafenib in advanced hepatocellular carcinoma. | N Engl J Med | 2008 | https://conductscience.org/library/papers/18650514 | PubMed |
| 2 | 29532289 | Platelet function is disturbed by the angiogenesis inhibitors sunitinib and sorafenib, but unaffected by bevacizumab. | Angiogenesis | 2018 | https://conductscience.org/library/papers/29532289 | PubMed |
| 3 | 17519900 | Mechanisms of adverse effects of anti-VEGF therapy for cancer. | Br J Cancer | 2007 | https://conductscience.org/library/papers/17519900 | PubMed |
| 4 | 30539828 | Bleeding risk in cancer patients treated with sorafenib: A meta-analysis of randomized controlled trials. | J Cancer Res Ther | 2018 | https://conductscience.org/library/papers/30539828 | PubMed |
| 5 | 36798021 | Comparison of a viscoelastic point-of-care coagulation monitor with thromboelastography in sick dogs with hemostatic abnormalities. | Vet Clin Pathol | 2023 | https://conductscience.org/library/papers/36798021 | PubMed |
| 6 | 37532540 | Toceranib phosphate and firocoxib-mediated partial response in a dog with advanced intranasal sarcoma. | J Vet Med Sci | 2023 | https://conductscience.org/library/papers/37532540 | PubMed |
| 7 | 17215530 | Sorafenib in advanced clear-cell renal-cell carcinoma. | N Engl J Med | 2007 | https://conductscience.org/library/papers/17215530 | PubMed |
| 8 | 39496212 | Point-of-care viscoelastic coagulation monitoring device shows promise for informing resuscitation strategies in a canine hemorrhagic shock model. | Am J Vet Res | 2025 | https://conductscience.org/library/papers/39496212 | PubMed |
| 9 | 15466206 | BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. | Cancer Res | 2004 | https://conductscience.org/library/papers/15466206 | PubMed |
| 10 | 39126006 | Immunohistochemistry Screening of Different Tyrosine Kinase Receptors in Canine Solid Tumors-Part I: Proposal of a Receptor Panel to Predict Therapies. | Int J Mol Sci | 2024 | https://conductscience.org/library/papers/39126006 | PubMed |
| 11 | 32443457 | Sorafenib for the Treatment of Unresectable Hepatocellular Carcinoma: Preliminary Toxicity and Activity Data in Dogs. | Cancers (Basel) | 2020 | https://conductscience.org/library/papers/32443457 | PubMed |
| 12 | 33368568 | Establishment of normal reference intervals in dogs using a viscoelastic point-of-care coagulation monitor and its comparison with thromboelastography. | Vet Clin Pathol | 2020 | https://conductscience.org/library/papers/33368568 | PubMed |
| 13 | 24768112 | Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. | Lancet | 2014 | https://conductscience.org/library/papers/24768112 | PubMed |
| 14 | 30050861 | Tolerability of oral sorafenib in pet dogs with a diagnosis of cancer. | Vet Med (Auckl) | 2017 | https://conductscience.org/library/papers/30050861 | PubMed |
| 15 | 19581909 | Adverse effects of anticancer agents that target the VEGF pathway. | Nat Rev Clin Oncol | 2009 | https://conductscience.org/library/papers/19581909 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Cited by
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/42017533
GET https://conductscience.org/api/papers/v1/42017533/authors